S-1: Nordicus Partners Corporation Files for Resale of 16.2 Million Common Shares

Nordicus Partners Corporation has filed a registration statement for the resale of 16,190,911 shares of its common stock by existing shareholders.

Summary

• Nordicus Partners Corporation, a financial consulting company, has filed an S-1 registration statement for the resale of 16,190,911 shares of its common stock.
• The company specializes in assisting Nordic and U.S. life science companies with market entry and corporate finance.
• The selling stockholders, including the CEO and entities like AC Nordic, Alteral Therapeutics, and GK Partners, currently hold approximately 69% of the outstanding shares.
• The company will not receive any proceeds from the sale of these shares.
• Nordicus Partners was founded in 1993, reincorporated in Delaware in 2007, and has undergone several name changes, most recently in 2023.
• The company has made several acquisitions, including a 4.99% interest in Mag Mile Capital, a 95% interest in Orocidin A/S, and an agreement to acquire Bio-Convert ApS.
• A 1:10 reverse stock split was implemented on November 8, 2024.
• As a smaller reporting company, Nordicus Partners has reduced disclosure requirements.
• The company's common stock is quoted on the OTCQB Market under the symbol NORD, with a last reported sale price of $2.76 on December 6, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a clear strategy and has made strategic acquisitions, it faces significant financial challenges, including minimal revenue, operating losses, and concerns about its ability to continue as a going concern. The high level of control by a few shareholders and the penny stock status of its shares also raise concerns.

Positives

• The company has a clear growth strategy focused on leveraging management's expertise to advise Nordic and international companies.
• The company has a comprehensive network of business partners and associates across Europe and the U.S.
• The company operates as a business incubator, providing support resources for companies transitioning to the U.S. market.
• The company has made strategic acquisitions to expand its business, including Orocidin A/S and Bio-Convert ApS.

Negatives

• The company has a limited operating history and has not generated significant revenue to date.
• The company has incurred significant operating losses and may continue to do so.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company's common stock is considered a penny stock and may be difficult to sell.
• The company's management has limited experience in operating a public company.
• A small number of shareholders control a significant majority of the outstanding shares.
• The company is subject to the periodic reporting requirements of the Exchange Act, which will require it to incur audit and legal fees.
• The company may be exposed to potential risks resulting from new requirements under Section 404 of the Sarbanes-Oxley Act of 2002.

Risks

• There is no assurance of an active established public trading market for the company's stock.
• The company's common stock is considered a penny stock and may be difficult to sell.
• A decline in the price of the company's common stock could affect its ability to raise additional working capital.
• The company does not intend to pay dividends, and stockholders may not experience a return on investment without selling their securities.
• Unfavorable general economic conditions may materially adversely affect the company's business.
• The company may not be able to maintain effective internal controls over financial reporting.
• The company's management has limited experience in operating a public company.
• A significant majority of the company's outstanding shares are held by a small number of shareholders.
• The company is subject to the periodic reporting requirements of the Exchange Act, which will require it to incur audit and legal fees.
• The company may be exposed to potential risks resulting from new requirements under Section 404 of the Sarbanes-Oxley Act of 2002.
• The capital markets may experience periods of disruption and instability.
• The company is a start-up company and may be unable to generate significant revenues and may never become profitable.
• The company's growth and financial performance will depend on future accretive acquisitions.
• The company's future capital needs are uncertain, and its independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company may not be able to correctly estimate its future operating expenses, which could lead to cash shortfalls.
• The company's operating results may fluctuate as a result of a number of factors.
• The company expects to need additional substantial capital to fund its growing operations.
• The company will operate in an ever-evolving industry, and changes to it can have a material effect on its business model.
• If the company does not effectively manage its anticipated growth, its operating performance will suffer.
• The company needs to hire and retain additional qualified personnel to grow and manage its business.
• If the company fails to compete effectively against other competitors, it could fail to attract customers.
• Limitations on director and officer liability and the company's indemnification of its officers and directors may discourage stockholders from bringing suit against a director.
• If the company fails to maintain an effective system of internal control over financial reporting, this may result in material misstatements of its consolidated financial statements.
• The company will face increased legal, accounting, administrative and other costs and expenses as a public company.
• Privacy concerns and laws, or other regulations, may adversely affect the company's business.
• The warrants are being accounted for as a warrant liability and are being recorded at fair value upon issuance.
• The company has never paid cash dividends on its capital stock and does not anticipate paying dividends in the foreseeable future.
• The company's stock price will be volatile, and you may not be able to sell shares at or above the price at which shares of its common stock in this registration statement are purchased.
• The market price of the company's common stock could be adversely affected by sales of substantial amounts of its common stock.
• If securities or industry analysts do not publish or cease publishing research or reports about the company, its business, or its market, the price and trading volume of its securities could decline.
• The company's bylaws include a forum selection clause, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes with the company.

Future Outlook

The company intends to retain all available funds and any future earnings for use in financing the growth of its business and does not anticipate paying any cash dividends for the foreseeable future.

Management Comments

• Our mission going forward, is to assist the right Nordic companies realize their growth strategy, by fine tuning systems and processes, sharpening the commercial focus and providing companies with the best possible guidance and setup suited to successfully establish themselves on the U.S. market.
• Through our business operations, we are being presented with numerous business opportunities and ventures.
• On occasion we view some of those businesses attractive enough to engage with ourselves and thus acquire an ownership stake in the company.

Industry Context

The company operates in the financial consulting industry, specifically targeting Nordic and U.S. life science companies, which is a niche market with potential for growth given the increasing globalization of the healthcare sector.

Comparison to Industry Standards

• The company's financial performance is not directly comparable to established consulting firms due to its early stage and focus on a niche market.
• The company's revenue is minimal compared to larger consulting firms, which often have established client bases and recurring revenue streams.
• The company's reliance on acquisitions for growth is a common strategy in the consulting industry, but the success of this strategy depends on the integration of acquired businesses and the realization of synergies.
• The company's focus on life science companies is similar to other specialized consulting firms, but its emphasis on Nordic companies is a unique differentiator.
• The company's lack of profitability and negative cash flow are common challenges for early-stage companies, but the company's ability to raise capital and achieve profitability will be critical for its long-term success.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings.

Related Party Transactions

• The company has engaged in several transactions with GK Partners, including the issuance of warrants and the sale of shares of Mag Mile Capital, Inc.
• The company has paid legal fees to a firm affiliated with its CFO, Bennett J. Yankowitz.
• The company has employment and consulting agreements with its CEO, Henrik Rouf, and CFO, Bennett J. Yankowitz, respectively.
• A related party forgave a payable of $13,886, which was credited to additional paid-in capital.

Stakeholder Impact

• Shareholders may experience volatility in the stock price and may not receive dividends in the foreseeable future.
• Employees may benefit from the 2024 Stock Incentive Plan.
• Customers may benefit from the company's expertise in assisting with market entry and corporate finance.
• Suppliers may benefit from the company's growth and expansion.
• Creditors may be at risk due to the company's financial challenges and going concern issues.

Next Steps

• The company intends to continue to expand its business through strategic acquisitions.
• The company intends to continue to provide consulting services to Nordic and U.S. life science companies.
• The company intends to continue to seek additional funding through the sale of its securities, grants or other forms of financing.

Key Dates

Keywords

financial consulting, life science, Nordic companies, corporate finance, reverse stock split, OTCQB, biopharmaceutical, acquisitions, capital raise, penny stock